DNA Repair Drugs Market to Grow Substantially due to Increasing Cancer Incidence

The DNA repair drugs market has been growing rapidly over the past few years owing to the rising incidence of cancer across the globe. DNA repair drugs aim to restore normal DNA damage response pathways in cancer cells by inducing synthetic lethality. These drugs target DNA repair pathways like base excision repair, nucleotide excision repair, mismatch repair, and homologous recombination. Commonly used DNA repair drugs are PARP inhibitors, alkylating agents, and platinum-based compounds. PARP inhibitors are gaining significant traction in the breast and ovarian cancers treatment. DNA repair drugs offer minimal toxic effects and wide therapeutic index.

The global DNA repair drugs market is estimated to be valued at US$ 7.24 Mn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period from 2024 to 2030.

Key Takeaways

Key players operating in the DNA repair drugs are Accenture Plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc., GlaxoSmithKline, ICON, Plc, iGATE Corporation, Arriello, iMEDGlobal Corporation, Diamond Pharma Services, Infosys, Ergomed plc, inVentiv Health Inc., APCER Life Sciences, ArisGlobal, and Johnson and Johnson. Key players like Bristol-Myers Squibb and GlaxoSmithKline are focusing on developing innovative PARP inhibitors to capture higher market share.

With rising cancer burden, there lies immense potential for DNA repair drug therapies in the market. Development of combination therapies using DNA repair drugs along with chemotherapy and targeted therapies promise synergistic anti-tumor activity. Furthermore, exploration of new drug targets in DNA repair pathways like FANCA, FEN1, LIG1 will further boost market growth.

Geographically, North America dominated the global market and is expected to continue its dominance during the forecast period. However, Asia Pacific market is expected to exhibit fastest growth owing to increasing expenditure on healthcare, rising awareness about targeted cancer therapies.

Market drivers:

The key driver favoring the growth of DNA Repair Drugs Market is increasing prevalence of cancer worldwide. As per WHO, cancer burden is expected to reach 27.5 million new cancer cases by 2040. Moreover, rising approval and launch of novel DNA repair targeting drugs along with their strong pipeline will drive the market growth over the forecast period. Increased healthcare spending and demand for targeted therapies with minimal side effects are further expected to propel the market during next decade.

PEST Analysis

Political: The DNA Repair Drugs Market is regulated by various government agencies that approve and monitor new drugs. Regulations influence the development and approval of new DNA repair drugs.

Economic: Changes in healthcare spending and the overall economy can affect the demand for new DNA repair drugs from patients and hospitals. Research and development investments by pharmaceutical companies also depend on the economic environment.

Social: As life expectancy increases, age-related diseases are on the rise. This drives demand for new therapies to treat cancers and other genetic disorders. Growing health awareness in the public promotes preventive healthcare using drugs that repair DNA damage.

Technological: Advances in biotechnology and genetic research aid the understanding of DNA repair mechanisms. This enables development of targeted drugs that interfere with specific pathways. Companies invest significantly in R&D utilizing new tools from fields like structural biology, genomics and bioinformatics.

The DNA Repair Drugs Market in terms of value is concentrated majorly in North America and Western Europe. countries like United States, Germany, France and United Kingdom account for over 60% of the global market revenue. This is due to high healthcare spending, presence of leading research institutes and pharmaceutical companies in these regions.

Asia Pacific region is the fastest growing market for DNA Repair Drugs. Countries like China, Japan and India are witnessing increased usage of newer targeted therapies. Rising income levels, growing medical infrastructure and expanding health insurance coverage are driving strong demand growth above global average rates in Asia Pacific.

Get more insights on this topic: https://www.insightprobing.com/global-dna-repair-drugs-market-insights/